Cargando…

Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter international study

OBJECTIVES: This retrospective chart review examined real‐world healthcare resource utilization (HRU) in patients with AML ineligible for intensive therapy who received first‐line systemic therapy or best supportive care (BSC). METHODS: Data were collected anonymously on patients with AML who initia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Tomoki, Sanford, David, Tomuleasa, Ciprian, Hsiao, Hui‐Hua, Olivera, Leonardo José Enciso, Enjeti, Anoop Kumar, Conca, Alberto Gimenez, del Castillo, Teresa Bernal, Girshova, Larisa, Martelli, Maria Paola, Guvenc, Birol, Bui, Cat N., Delgado, Alex, Duan, Yinghui, Guijarro, Belen Garbayo, Llamas, Cynthia, Lee, Je‐Hwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324937/ https://www.ncbi.nlm.nih.gov/pubmed/35298049 http://dx.doi.org/10.1111/ejh.13769

Ejemplares similares

Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy
por: Iluta, Sabina, et al.
Publicado: (2021)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

Real-World Treatment Patterns and Clinical Outcomes in Korean Patients With AML Ineligible for First-Line Intensive Chemotherapy: A Subanalysis of the CURRENT Study, a Non-Interventional, Retrospective Chart Review
por: Bang, Soo-Mee, et al.
Publicado: (2023)

Removal of ineligible outcome cases reduces confounding
por: Walker, Alexander M, et al.
Publicado: (2018)

Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents
por: Nakaya, Aya, et al.
Publicado: (2017)

Beyond abstraction: applying the brakes to runaway patent ineligibility
por: Burk, Dan L.
Publicado: (2016)

Targeting Apoptotic Pathways in Acute Myeloid Leukaemia
por: Sillar, Jonathan R., et al.
Publicado: (2019)

The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience
por: Açar, İbrahim Halil, et al.
Publicado: (2023)

Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience
por: Açar, İbrahim Halil, et al.
Publicado: (2023)

How I manage frontline transplant-ineligible multiple myeloma
por: Derudas, Daniele, et al.
Publicado: (2020)

Notification Strategy and Predictors of Outcome in Stroke Ineligible for Reperfusion Therapies
por: Mirolovics, Ágnes, et al.
Publicado: (2019)

Office-Based Laryngeal Biopsy in Patients Ineligible for General Anesthesia
por: Mozzanica, Francesco, et al.
Publicado: (2020)

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma
por: Marin-Acevedo, Julian A., et al.
Publicado: (2023)

How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Percutaneous Radiofrequency Ablation of Thyroid Carcinomas Ineligible for Surgery, in the Elderly
por: Marcy, Pierre Yves, et al.
Publicado: (2023)

Characteristics and Outcomes of Patients Ineligible for Transcatheter Mitral Valve Replacement
por: Hatab, Taha, et al.
Publicado: (2023)

Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy
por: Bond, Danielle R., et al.
Publicado: (2020)

Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy
por: Shao, I-Hung, et al.
Publicado: (2014)

Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed/Refractory T-Cell Lymphoma
por: Norasetthada, Lalita, et al.
Publicado: (2018)

Exclusion of enrolled participants in randomised controlled trials: what to do with ineligible participants?
por: Rehman, Andrea M, et al.
Publicado: (2020)

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
por: Blommestein, Hedwig M., et al.
Publicado: (2021)

Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?
por: Hambley, Bryan C., et al.
Publicado: (2021)

Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting
por: Nakaya, Aya, et al.
Publicado: (2020)

Genomic profiling of plasma cell disorders in a clinical setting: integration of microarray and FISH, after CD138 selection of bone marrow
por: Berry, Nadine Kaye, et al.
Publicado: (2014)

Circulating microvesicles in snakebite patients with microangiopathy
por: Enjeti, Anoop K., et al.
Publicado: (2018)

Microangiopathy in snake bites—bubble trouble: Response to commentary
por: Enjeti, Anoop K., et al.
Publicado: (2019)

Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial
por: Ueda, Akira, et al.
Publicado: (2013)

Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies
por: Pettit, Kristen, et al.
Publicado: (2015)

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
por: Seo, Kwang Il, et al.
Publicado: (2017)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Successful lung transplantation after prone positioning in an ineligible donor: a case report
por: Son, Eunjeong, et al.
Publicado: (2021)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Xia, Leiming, et al.
Publicado: (2023)

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
por: Fonseca, Rafael, et al.
Publicado: (2023)

Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies
por: Kimura, Tomoki, et al.
Publicado: (2018)

Minimally invasive enucleation with zero ischemia for malignancies. The Cluj Napoca experience
por: Gherman, Vitalie, et al.
Publicado: (2013)

The Potential Equivalents of TET2 Mutations
por: Pasca, Sergiu, et al.
Publicado: (2021)

TET2/IDH1/2/WT1 and NPM1 Mutations Influence the RUNX1 Expression Correlations in Acute Myeloid Leukemia
por: Pasca, Sergiu, et al.
Publicado: (2020)

Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases
por: Marinelli, Sara, et al.
Publicado: (2013)

Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis
por: Lyu, Wen-Wen, et al.
Publicado: (2016)

Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation
por: Choi, Yong Won, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q6lm3c0kvo9hde5o1r9ovgngl1